Powered by: Motilal Oswal
2026-09-30 09:25:52 am | Source: Motilal Oswal Financial Services Ltd Ltd
Buy Aster DM Quality Care Ltd for the Target Rs 910 by Motilal Oswal Financial Services Ltd
Buy Aster DM Quality Care Ltd for the Target Rs 910 by Motilal Oswal Financial Services Ltd

Building a healthcare giant

* The Aster DM Healthcare–QCIL merger creates one of India's largest hospital platforms, Aster DM Quality Care (AsterDM), with 39 hospitals and ~10,600 operational beds across 28 cities. The platform has capacity to scale beyond 15,000 beds by FY30 through a balanced brownfield/greenfield/asset-light approach.

* A cluster-led strategy anchors the growth story, with Kerala's mature, highmargin base complemented by a faster-growing Karnataka/Maharashtra and AP/Telangana footprint, providing both earnings stability and a long growth runway. ? The QCIL merger meaningfully deepens regional diversification, bringing a complementary set of hospital networks under one roof and creating a genuinely pan-India platform with stronger potential for cross-cluster referrals.

* Prior to the QCIL merger, AsterDM had already demonstrated a growthplus-margin story (revenue +12% YoY in FY25/FY26 to INR41b/46b, alongside ~300bp/90bp margin gains), with momentum carrying into 1QFY27 (+22%/27% revenue/EBITDA YoY) and FY26 proforma combined revenue/EBITDA of INR92.7b/INR20b (+14%/21% YoY). We expect revenue/EBITDA/PAT to deliver 19.5%/25%/33% CAGR over FY26-28, reaching INR132b/INR30.7b/INR16.5, respectively, aided by procurement, clinical, and cost synergies.

* We initiate coverage with a BUY rating, valuing ASTERDM at 27x 12M forward EBITDA (INR30.7b) to arrive at a TP of INR910 (20% upside from INR759), with bull/bear scenarios of INR1,110/INR735 hinging on the pace of QCIL synergy realization and capacity ramp-up.

Building one of India's largest integrated hospital networks

* The Aster DM Healthcare–QCIL merger creates one of India’s largest hospital platforms, with 39 hospitals and ~10,600 operational beds (10,898 capacity beds), providing a scaled presence across key healthcare markets.

* The combined entity plans to add 4,150+ beds by FY30, taking total capacity to 15,000+ beds through a balanced mix of brownfield, greenfield, and assetlight projects, with expansion focused on high-growth clusters such as Trivandrum, Bengaluru, Hyderabad, and Chennai.

Cluster-led strategy to drive sustainable growth

* Kerala remains the largest contributor, accounting for 53% of FY26 hospital revenue pre-merger, supported by mature assets, quaternary care, and medical value travel. Growth is expected to be driven by the 454-bed Trivandrum expansion and other brownfield additions.

* Karnataka/Maharashtra and AP/Telangana offer a strong growth runway, contributing 34%/13% of FY26 revenue, supported by a higher-acuity mix, improving ARPOB/occupancy, and capacity additions at Sarjapur, Yeshwanthpur, and the 300-bed Hyderabad Women & Children’s hospital.

* The QCIL merger further strengthens ASTERDM’s regional presence by adding leading hospital networks across Hyderabad, Trivandrum, Nagpur, Indore, Raipur, Bhubaneswar, and other key cities, creating a more balanced pan-India platform with greater referral opportunities and cross-cluster synergies.

* Mature assets remain a significant earnings base, contributing ~65% of 1QFY27 revenue (+19% YoY) at a healthy 29.7% EBITDA margin, while emerging hospitals grew 63% YoY, providing further upside as these assets mature.

Valuation and view: Initiate coverage with a BUY rating

* We value ASTERDM using EV/EBITDA, with a base-case 12M forward EBITDA of INR27.7b and 27x multiple, implying a TP of INR910 and 20% upside from INR759.

* Bull case: TP of INR1,110 (46% upside), assuming faster QCIL integration, stronger synergies, occupancy/ARPOB gains, and a higher MVT/complex-care share.

* Bear case: TP of INR700 (8% downside), reflecting slower synergies, delayed capacity ramp-up, weaker occupancy, and continued post-merger cost pressures.

Key risks

* QCIL integration and delays in synergy realization could weigh on margins

* Expansion delays could defer growth and weaken RoCE

* Regulatory changes and price caps could pressure profitability

 

For More Research Reports : Click Here 

For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here